PRP8 Polyclonal Antibody

Rabbit Anti-PRP8 Polyclonal Antibody

Product Specifications

Background

Pre-mRNA splicing occurs in 2 sequential transesterification steps. The protein encoded by PRPF8 (Pre-MRNA Processing Factor 8) is a component of both U2- and U12-dependent spliceosomes, and found to be essential for the catalytic step II in pre-mRNA splicing process. It contains several WD repeats, which function in protein-protein interactions. This protein has a sequence similarity to yeast Prp8 protein. PRPF8 is a candidate gene for autosomal dominant retinitis pigmentosa.

CAS Number

9007-83-4

Product Name Alternative

Pre-mRNA-processing-splicing factor 8; 220 kDa U5 snRNP-specific protein; PRP8 homolog; Splicing factor Prp8; p220

Gene ID

10594

Accession Number

Q6P2Q9

Reactivity

Human, Mouse

Immunogen

Synthesized peptide derived from part region of human PRP8 protein at amino acid sequence of 160-240

Clonality

Polyclonal

Tag

PRP8

Applications

IHC, IF

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

256kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

The antibody detects endogenous levels of PRP8 protein

Observed Molecular Weight

256

Formulation

Liquid solution

Buffer pH

PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:50-300; IF 1:50-200